(NEW) Guidepoint Qsight Models: SYK & BSX
by Kenny Dolgin, Healthcare Analyst, Data Insights, Guidepoint
Guidepoint’s Data Insights team is excited to announce that we have expanded Guidepoint Qsight’s data product offering to include models for Stryker (“SYK”) and Boston Scientific (“BSX”).
Prior to Stryker’s Q3 2018 earnings release, Qsight’s data and projection methodology showed potential for their U.S. revenue to come in below sell-side consensus estimates. On October 25th, Stryker’s Q3 2018 reported U.S. sales underperformed Street expectations, sending the stock price down -3% the next day.
Prior to Boston’s Q3 2018 earnings release, Qsight’s data and projection methodology showed potential for their U.S. revenue to come in above sell-side consensus estimates. On October 24th, Boston’s Q3 2018 reported U.S. sales outperformed Street expectations, sending the stock price up +2% the next day.
Guidepoint Qsight’s U.S. hospital purchasing data captures medical products and devices purchased by over 1,500 hospitals. The monthly data is updated on a weekly basis which allows for near real-time capture of actual spend, market growth, pricing dynamics and market share shifts among manufacturers. Qsight utilizes the data and provides revenue projections for the upcoming quarter via easy-to-use Excel models. Below is a list of Qsight’s product models currently offered:
Edwards Lifesciences (EW), Abiomed (ABMD), Penumbra (PEN), Intersect ENT (XENT), Wright Medical (WMGI), Zimmer Biomet (ZBH), Intuitive Surgical (ISRG), Smith & Nephew (SNN), Cardiovascular Systems (CSII), Atricure (ATRC), (NEW) Boston Scientific (BSX), (NEW) Stryker (SYK)
For a free demo of Qsight, please click below:
Guidepoint is not a registered investment adviser and cannot transact business as an investment adviser or give investment advice. The information, analyses, forecasts, metrics, samples, estimated figures, trends, charts, tables, graphs, and projections contained herein or in any Guidepoint Data Product do not represent, contain or constitute investment advice and are not intended as an offer to sell or solicitation of an offer to buy any security, or as a recommendation to buy or sell any security and should not be relied upon as the basis for any transactions in securities.